{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:29:03Z","timestamp":1784896143330,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00034"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00034"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","award":["EFOP-3.6.1-16-2016-00008"],"award-info":[{"award-number":["EFOP-3.6.1-16-2016-00008"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","award":["20391-3\/2018\/FEKUSTRAT"],"award-info":[{"award-number":["20391-3\/2018\/FEKUSTRAT"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hungarian Brain Research Program","award":["2017-1.2.1-NKP-2017-00002 NAP VI\/4"],"award-info":[{"award-number":["2017-1.2.1-NKP-2017-00002 NAP VI\/4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The potential role of Sirt1 and Sirt2 subtypes of Sirtuins (class III NAD<jats:sup>+<\/jats:sup>-dependent deacetylases) in the pathogenesis of Huntington\u2019s disease (HD) has been extensively studied yielding some controversial results. However, data regarding the involvement of Sirt3 and their variants in HD are considerably limited. The aim of this study was to assess the expression pattern of Sirt1 and three Sirt3 mRNA isoforms (Sirt3-M1\/2\/3) in the striatum, cortex and cerebellum in respect of the effect of gender, age and the presence of the transgene using the N171-82Q transgenic mouse model of HD. Striatal, cortical and cerebellar Sirt1-Fl and Sirt3-M1\/2\/3 mRNA levels were measured in 8, 12 and 16 weeks old N171-82Q transgenic mice and in their wild-type littermates. Regarding the striatum and cortex, the presence of the transgene resulted in a significant increase in Sirt3-M3 and Sirt1 mRNA levels, respectively, whereas in case of the cerebellum the transgene resulted in increased expression of all the assessed subtypes and isoforms. Aging exerted minor influence on Sirt mRNA expression levels, both in transgene carriers and in their wild-type littermates, and there was no interaction between the presence of the transgene and aging. Furthermore, there was no difference between genders. The unequivocal cerebellar Sirtuin activation with presumed compensatory role suggests that the cerebellum might be another key player in HD in addition to the most severely affected striatum. The mitochondrially acting Sirt3 may serve as an interesting novel therapeutic target in this deleterious condition.<\/jats:p>","DOI":"10.1007\/s11064-020-03069-0","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T13:03:45Z","timestamp":1591794225000},"page":"2072-2081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington\u2019s Disease"],"prefix":"10.1007","volume":"45","author":[{"given":"Andras","family":"Salamon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Maszlag-T\u00f6r\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Veres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni Annam\u00e1ria","family":"Boros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"V\u00e1gv\u00f6lgyi-S\u00fcmegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-7980","authenticated-orcid":false,"given":"D\u00e9nes","family":"Z\u00e1dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"3069_CR1","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1073\/pnas.0803790105","volume":"105","author":"BH Ahn","year":"2008","unstructured":"Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A et al (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 105:14447\u201314452. https:\/\/doi.org\/10.1073\/pnas.0803790105","journal-title":"Proc Natl Acad Sci USA"},{"key":"3069_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neubiorev.2016.11.022","volume":"73","author":"M Ajami","year":"2017","unstructured":"Ajami M, Pazoki-Toroudi H, Amani H, Nabavi SF, Braidy N, Vacca RA et al (2017) Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols. Neurosci Biobehav Rev 73:39\u201347. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.11.022","journal-title":"Neurosci Biobehav Rev"},{"key":"3069_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nature02998","volume":"431","author":"M Arrasate","year":"2004","unstructured":"Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805\u2013810. https:\/\/doi.org\/10.1038\/nature02998","journal-title":"Nature"},{"key":"3069_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/nan.12514","volume":"45","author":"B Baldo","year":"2019","unstructured":"Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E et al (2019) SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. Neuropathol Appl Neurobiol 45:361\u2013379. https:\/\/doi.org\/10.1111\/nan.12514","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3069_CR5","doi-asserted-by":"publisher","first-page":"e34805","DOI":"10.1371\/journal.pone.0034805","volume":"7","author":"A Bobrowska","year":"2012","unstructured":"Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G (2012) SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington\u2019s disease phenotypes in vivo. PLoS ONE 7:e34805. https:\/\/doi.org\/10.1371\/journal.pone.0034805","journal-title":"PLoS ONE"},{"key":"3069_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.neuroimage.2011.02.022","volume":"56","author":"Y Cheng","year":"2011","unstructured":"Cheng Y, Peng Q, Hou Z, Aggarwal M, Zhang J, Mori S et al (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington\u2019s disease mouse model. Neuroimage 56:1027\u20131034. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.02.022","journal-title":"Neuroimage"},{"key":"3069_CR7","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.celrep.2012.11.001","volume":"2","author":"V Chopra","year":"2012","unstructured":"Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C et al (2012) The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington\u2019s disease mouse models. Cell Rep 2:1492\u20131497. https:\/\/doi.org\/10.1016\/j.celrep.2012.11.001","journal-title":"Cell Rep"},{"key":"3069_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59\u201369. https:\/\/doi.org\/10.1016\/j.cell.2006.09.015","journal-title":"Cell"},{"key":"3069_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(95)90260-0","volume":"345","author":"AW Deckel","year":"1995","unstructured":"Deckel AW (1995) Is Huntington\u2019s disease of cerebellar\/brainstem origin? Lancet 345:263\u2013264. https:\/\/doi.org\/10.1016\/S0140-6736(95)90260-0","journal-title":"Lancet"},{"key":"3069_CR10","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","volume":"27","author":"JP Dompierre","year":"2007","unstructured":"Dompierre JP, Godin JD, Charrin BC, Cordeli\u00e8res FP, King SJ, Humbert S et al (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington\u2019s disease by increasing tubulin acetylation. J Neurosci 27:3571\u20133583. https:\/\/doi.org\/10.1523\/JNEUROSCI.0037-07.2007","journal-title":"J Neurosci"},{"key":"3069_CR11","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1073\/pnas.0536856100","volume":"USA100","author":"W Duan","year":"2003","unstructured":"Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA100:2911\u20132916. https:\/\/doi.org\/10.1073\/pnas.0536856100","journal-title":"Proc Natl Acad Sci"},{"key":"3069_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M et al (1993) Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat Genet 4:387\u2013392. https:\/\/doi.org\/10.1038\/ng0893-387","journal-title":"Nat Genet"},{"key":"3069_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S (2014) Treatment of Huntington\u2019s disease. Neurotherapeutics 11:153\u2013160. https:\/\/doi.org\/10.1007\/s13311-013-0244-z","journal-title":"Neurotherapeutics"},{"key":"3069_CR14","doi-asserted-by":"publisher","first-page":"24460","DOI":"10.1074\/jbc.M112.382226","volume":"287","author":"J Fu","year":"2012","unstructured":"Fu J, Jin J, Cichewicz RH, Hageman SA, Ellis TK, Xiang L et al (2012) Trans-(-)-\u03b5-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease. J Biol Chem 287:24460\u201324472. https:\/\/doi.org\/10.1074\/jbc.M112.382226","journal-title":"J Biol Chem"},{"key":"3069_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK et al (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 280:556\u2013563. https:\/\/doi.org\/10.1074\/jbc.M410210200","journal-title":"J Biol Chem"},{"key":"3069_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0896-6273(03)00594-4","volume":"40","author":"S Gunawardena","year":"2003","unstructured":"Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B et al (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25\u201340. https:\/\/doi.org\/10.1016\/s0896-6273(03)00594-4","journal-title":"Neuron"},{"key":"3069_CR17","first-page":"251","volume-title":"Huntington\u2019s disease","author":"CA Gutekunst","year":"2002","unstructured":"Gutekunst CA, Norflus F, Hersch SM (2002) The neuropathology of Huntington\u2019s disease. In: Bates GP, Harper PS, Jones AL (eds) Huntington\u2019s disease, 4th edn. OUP, Oxford, pp 251\u2013275","edition":"4"},{"key":"3069_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","volume":"41","author":"T Hathorn","year":"2011","unstructured":"Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis 41:43\u201350. https:\/\/doi.org\/10.1016\/j.nbd.2010.08.017","journal-title":"Neurobiol Dis"},{"key":"3069_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00247-018-4167-z","volume":"48","author":"A Hedjoudje","year":"2018","unstructured":"Hedjoudje A, Nicolas G, Goldenberg A, Vanhulle C, Dumant-Forrest C, Deverri\u00e8re G et al (2018) Morphological features in juvenile Huntington disease associated with cerebellar atrophy: magnetic resonance imaging morphometric analysis. Pediatr Radiol 48:1463\u20131471. https:\/\/doi.org\/10.1007\/s00247-018-4167-z","journal-title":"Pediatr Radiol"},{"key":"3069_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225:74\u201384. https:\/\/doi.org\/10.1016\/j.expneurol.2010.05.006","journal-title":"Exp Neurol"},{"key":"3069_CR21","doi-asserted-by":"publisher","first-page":"35391","DOI":"10.1038\/srep35391","volume":"6","author":"T Jayasena","year":"2016","unstructured":"Jayasena T, Poljak A, Braidy N, Zhong L, Rowlands B, Muenchhoff J et al (2016) Application of targeted mass spectrometry for the quantification of sirtuins in the central nervous system. Sci Rep 6:35391. https:\/\/doi.org\/10.1038\/srep35391","journal-title":"Sci Rep"},{"key":"3069_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR et al (2011) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18:159\u2013165. https:\/\/doi.org\/10.1038\/nm.2559","journal-title":"Nat Med"},{"key":"3069_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0014-4886(84)90162-6","volume":"85","author":"DV Jeste","year":"1984","unstructured":"Jeste DV, Barban L, Parisi J (1984) Reduced Purkinje cell density in Huntington\u2019s disease. Exp Neurol 85:78\u201386. https:\/\/doi.org\/10.1016\/0014-4886(84)90162-6","journal-title":"Exp Neurol"},{"key":"3069_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2011","unstructured":"Jiang M, Wang J, Fu J, Du L, Jeong H, West T et al (2011) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18:153\u2013158. https:\/\/doi.org\/10.1038\/nm.2558","journal-title":"Nat Med"},{"key":"3069_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12640-017-9766-1","volume":"32","author":"M Jodeiri Farshbaf","year":"2017","unstructured":"Jodeiri Farshbaf M, Ghaedi K (2017) Huntington\u2019s disease and mitochondria. Neurotox Res 32:518\u2013529. https:\/\/doi.org\/10.1007\/s12640-017-9766-1","journal-title":"Neurotox Res"},{"key":"3069_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1212\/WNL.0000000000002858","volume":"87","author":"C Kay","year":"2016","unstructured":"Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N et al (2016) Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 87:282\u2013288. https:\/\/doi.org\/10.1212\/WNL.0000000000002858","journal-title":"Neurology"},{"key":"3069_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nm.2624","volume":"18","author":"AR La Spada","year":"2012","unstructured":"La Spada AR (2012) Finding a sirtuin truth in Huntington\u2019s disease. Nat Med 18:24\u201326. https:\/\/doi.org\/10.1038\/nm.2624","journal-title":"Nat Med"},{"key":"3069_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/BJ20130414","volume":"454","author":"Q Liang","year":"2013","unstructured":"Liang Q, Benavides GA, Vassilopoulos A, Gius D, Darley-Usmar V, Zhang J (2013) Bioenergetic and autophagic control by Sirt3 in response to nutrient deprivation in mouse embryonic fibroblasts. Biochem J 454:249\u2013257. https:\/\/doi.org\/10.1042\/BJ20130414","journal-title":"Biochem J"},{"key":"3069_CR29","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1021\/bi400110b","volume":"52","author":"DC Liebler","year":"2013","unstructured":"Liebler DC, Zimmerman LJ (2013) Targeted quantitation of proteins by mass spectrometry. Biochemistry 52:3797\u20133806. https:\/\/doi.org\/10.1021\/bi400110b","journal-title":"Biochemistry"},{"key":"3069_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"3069_CR31","doi-asserted-by":"publisher","first-page":"e13502","DOI":"10.1371\/journal.pone.0013502","volume":"5","author":"CJ Lynch","year":"2010","unstructured":"Lynch CJ, Shah ZH, Allison SJ, Ahmed SU, Ford J, Warnock LJ et al (2010) SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS ONE 5:e13502. https:\/\/doi.org\/10.1371\/journal.pone.0013502","journal-title":"PLoS ONE"},{"key":"3069_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/wnl.53.6.1330","volume":"53","author":"ME MacDonald","year":"1999","unstructured":"MacDonald ME, Vonsattel JP, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED et al (1999) Evidence for the GluR6 gene associated with younger onset age of Huntington\u2019s disease. Neurology 53:1330\u20131332. https:\/\/doi.org\/10.1212\/wnl.53.6.1330","journal-title":"Neurology"},{"key":"3069_CR33","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1093\/hmg\/ddr326","volume":"20","author":"MM Maxwell","year":"2011","unstructured":"Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L et al (2011) The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet 20:3986\u20133996. https:\/\/doi.org\/10.1093\/hmg\/ddr326","journal-title":"Hum Mol Genet"},{"key":"3069_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jnr.22239","volume":"88","author":"SR Mirandola","year":"2010","unstructured":"Mirandola SR, Melo DR, Saito A, Castilho RF (2010) 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions. J Neurosci Res 88:630\u2013639. https:\/\/doi.org\/10.1002\/jnr.22239","journal-title":"J Neurosci Res"},{"key":"3069_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21307\/ane-2017-017","volume":"76","author":"MF Moln\u00e1r","year":"2016","unstructured":"Moln\u00e1r MF, T\u00f6r\u00f6k R, Szal\u00e1rdy L, S\u00fcmegi E, V\u00e9csei L, Kliv\u00e9nyi P (2016) High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington\u2019s disease transgenic mice. Acta Neurobiol Exp (Wars) 76:176\u2013181. https:\/\/doi.org\/10.21307\/ane-2017-017","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"3069_CR36","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.bbadis.2015.07.003","volume":"1852","author":"L Naia","year":"2015","unstructured":"Naia L, Rego AC (2015) Sirtuins: double players in Huntington\u2019s disease. Biochim Biophys Acta 1852:2183\u20132194. https:\/\/doi.org\/10.1016\/j.bbadis.2015.07.003","journal-title":"Biochim Biophys Acta"},{"key":"3069_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-801893-4.00001-8","volume":"144","author":"MA Nance","year":"2017","unstructured":"Nance MA (2017) Genetics of Huntington disease. Handb Clin Neurol 144:3\u201314. https:\/\/doi.org\/10.1016\/B978-0-12-801893-4.00001-8","journal-title":"Handb Clin Neurol"},{"key":"3069_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/bs.pmbts.2017.11.013","volume":"154","author":"SH Neo","year":"2017","unstructured":"Neo SH, Tang BL (2017) Sirtuins as modifiers of Huntington\u2019s disease (HD) pathology. Prog Mol Biol Transl 154:105\u2013145. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.11.013","journal-title":"Prog Mol Biol Transl"},{"key":"3069_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1126\/science.1117728","volume":"310","author":"E Nisoli","year":"2005","unstructured":"Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L et al (2005) Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310:314\u2013317. https:\/\/doi.org\/10.1126\/science.1117728","journal-title":"Science"},{"key":"3069_CR40","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1111\/j.1742-4658.2008.06612.x","volume":"275","author":"J Ol\u00e1h","year":"2008","unstructured":"Ol\u00e1h J, Kliv\u00e9nyi P, Gardi\u00e1n G, V\u00e9csei L, Orosz F, Kovacs GG et al (2008) Increased glucose metabolism and ATP level in brain tissue of Huntington\u2019s disease transgenic mice. FEBS J 275:4740\u20134755. https:\/\/doi.org\/10.1111\/j.1742-4658.2008.06612.x","journal-title":"FEBS J"},{"key":"3069_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/157488908783421492","volume":"3","author":"M Pall\u00e0s","year":"2008","unstructured":"Pall\u00e0s M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A (2008) Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov 3:61\u201369. https:\/\/doi.org\/10.2174\/157488908783421492","journal-title":"Recent Pat CNS Drug Discov"},{"key":"3069_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1051\/medsci\/2005215556","volume":"37","author":"JA Parker","year":"2005","unstructured":"Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H et al (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349\u2013350. https:\/\/doi.org\/10.1051\/medsci\/2005215556","journal-title":"Nat Genet"},{"key":"3069_CR43","doi-asserted-by":"publisher","first-page":"RRN1201","DOI":"10.1371\/currents.RRN1201","volume":"2","author":"MC Potter","year":"2010","unstructured":"Potter MC, Yuan C, Ottenritter C, Mughal M, van Praag H (2010) Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington\u2019s disease. PLoS Curr 2:RRN1201. https:\/\/doi.org\/10.1371\/currents.RRN1201","journal-title":"PLoS Curr"},{"key":"3069_CR44","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/mds.25984","volume":"29","author":"EM Rees","year":"2014","unstructured":"Rees EM, Farmer R, Cole JH, Haider S, Durr A, Landwehrmeyer B (2014) Cerebellar abnormalities in Huntington\u2019s disease: a role in motor and psychiatric impairment? Mov Disord 29:1648\u20131654. https:\/\/doi.org\/10.1002\/mds.25984","journal-title":"Mov Disord"},{"key":"3069_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.mcn.2017.12.009","volume":"88","author":"RH Reynolds","year":"2018","unstructured":"Reynolds RH, Petersen MH, Willert CW, Heinrich M, Nymann N, Dall M et al (2018) Perturbations in the p53\/miR-34a\/SIRT1 pathway in the R6\/2 Huntington\u2019s disease model. Mol Cell Neurosci 88:118\u2013129. https:\/\/doi.org\/10.1016\/j.mcn.2017.12.009","journal-title":"Mol Cell Neurosci"},{"key":"3069_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0022-510x(81)90049-6","volume":"50","author":"RA Rodda","year":"1981","unstructured":"Rodda RA (1981) Cerebellar atrophy in Huntington\u2019s disease. J Neurol Sci 50:147\u201357. https:\/\/doi.org\/10.1016\/0022-510x(81)90049-6","journal-title":"J Neurol Sci"},{"key":"3069_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neulet.2019.01.003","volume":"698","author":"A Salamon","year":"2019","unstructured":"Salamon A, T\u00f6r\u00f6k R, S\u00fcmegi E, Boros F, Pesei ZG, Fort Moln\u00e1r M et al (2019) The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis. Neurosci Lett 698:13\u201318. https:\/\/doi.org\/10.1016\/j.neulet.2019.01.003","journal-title":"Neurosci Lett"},{"key":"3069_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000460818","volume":"17","author":"M Samson","year":"2017","unstructured":"Samson M, Claassen DO (2017) Neurodegeneration and the cerebellum. Neurodegener Dis 17:155\u2013165. https:\/\/doi.org\/10.1159\/000460818","journal-title":"Neurodegener Dis"},{"key":"3069_CR49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397\u2013407. https:\/\/doi.org\/10.1093\/hmg\/8.3.397","journal-title":"Hum Mol Genet"},{"key":"3069_CR50","first-page":"65","volume":"5","author":"J Schulte","year":"2011","unstructured":"Schulte J, Littleton JT (2011) The biological function of the Huntingtin protein and its relevance to Huntington\u2019s disease pathology. Curr Trends Neurol 5:65\u201378","journal-title":"Curr Trends Neurol"},{"key":"3069_CR51","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ana.25413","volume":"85","author":"MK Singh-Bains","year":"2019","unstructured":"Singh-Bains MK, Mehrabi NF, Sehji T, Austria MDR, Tan AYS, Tippett LJ et al (2019) Cerebellar degeneration correlates with motor symptoms in Huntington disease. Ann Neurol 85:396\u2013405. https:\/\/doi.org\/10.1002\/ana.25413","journal-title":"Ann Neurol"},{"key":"3069_CR52","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","volume":"23","author":"MR Smith","year":"2014","unstructured":"Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA et al (2014) A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington\u2019s disease. Hum Mol Genet 23:2995\u20133007. https:\/\/doi.org\/10.1093\/hmg\/ddu010","journal-title":"Hum Mol Genet"},{"key":"3069_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1046\/j.1468-1331.2003.00601.x","volume":"10","author":"F Squitieri","year":"2003","unstructured":"Squitieri F, Pustorino G, Cannella M, Toscano A, Maglione V, Morgante L (2003) Highly disabling cerebellar presentation in Huntington disease. Eur J Neurol 10:443\u2013444. https:\/\/doi.org\/10.1046\/j.1468-1331.2003.00601.x","journal-title":"Eur J Neurol"},{"key":"3069_CR54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"SD S\u00fcssmuth","year":"2015","unstructured":"S\u00fcssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G et al (2015) An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol 79:465\u2013476. https:\/\/doi.org\/10.1111\/bcp.12512","journal-title":"Br J Clin Pharmacol"},{"key":"3069_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000346267","volume":"12","author":"L Szalardy","year":"2013","unstructured":"Szalardy L, Zadori D, Plangar I, Vecsei L, Weydt P, Ludolph AC (2013) Neuropathology of partial PGC-1\u03b1 deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neurodegener Dis 12:177\u2013188. https:\/\/doi.org\/10.1159\/000346267","journal-title":"Neurodegener Dis"},{"key":"3069_CR56","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA (2019) Targeting Huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380:2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"key":"3069_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0304-3940(93)90105-t","volume":"150","author":"M Takada","year":"1993","unstructured":"Takada M, Sugimoto T, Hattori T (1993) MPTP neurotoxicity to cerebellar Purkinje cells in mice. Neurosci Lett 150:49\u201352. https:\/\/doi.org\/10.1016\/0304-3940(93)90105-t","journal-title":"Neurosci Lett"},{"key":"3069_CR58","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10571-014-0124-z","volume":"35","author":"R Torok","year":"2015","unstructured":"Torok R, Konya JA, Zadori D, Veres G, Szalardy L, Vecsei L et al (2015) mRNA expression levels of PGC-1\u03b1 in a transgenic and a toxin model of Huntington\u2019s disease. Cell Mol Neurobiol 35:293\u2013301. https:\/\/doi.org\/10.1007\/s10571-014-0124-z","journal-title":"Cell Mol Neurobiol"},{"key":"3069_CR59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10571-014-0124-z","volume":"35","author":"R T\u00f6r\u00f6k","year":"2015","unstructured":"T\u00f6r\u00f6k R, K\u00f3nya JA, Z\u00e1dori D, Veres G, Szal\u00e1rdy L, V\u00e9csei L et al (2015) mRNA expression levels of PGC-1\u03b1 in a transgenic and a toxin model of Huntington\u2019s disease. Cell Mol Neurobiol 35:293\u2013301. https:\/\/doi.org\/10.1007\/s10571-014-0124-z","journal-title":"Cell Mol Neurobiol"},{"key":"3069_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brainres.2017.01.032","volume":"1660","author":"R T\u00f6r\u00f6k","year":"2017","unstructured":"T\u00f6r\u00f6k R, Salamon A, S\u00fcmegi E, Z\u00e1dori D, Veres G, Moln\u00e1r MF et al (2017) Effect of MPTP on mRNA expression of PGC-1\u03b1 in mouse brain. Brain Res 1660:20\u201326. https:\/\/doi.org\/10.1016\/j.brainres.2017.01.032","journal-title":"Brain Res"},{"key":"3069_CR61","doi-asserted-by":"publisher","first-page":"e0145425","DOI":"10.1371\/journal.pone.0145425","volume":"11","author":"R Tulino","year":"2016","unstructured":"Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A et al (2016) SIRT1 activity is linked to its brain region-specific phosphorylation and is impaired in Huntington\u2019s disease mice. PLoS ONE 11:e0145425. https:\/\/doi.org\/10.1371\/journal.pone.0145425","journal-title":"PLoS ONE"},{"key":"3069_CR62","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00702-009-0253-6","volume":"116","author":"E Vamos","year":"2009","unstructured":"Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P (2009) Neuroprotective effects of probenecid in a transgenic animal model of Huntington\u2019s disease. J Neural Transm (Vienna) 116:1079\u20131086. https:\/\/doi.org\/10.1007\/s00702-009-0253-6","journal-title":"J Neural Transm (Vienna)"},{"key":"3069_CR63","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.biopha.2009.06.020","volume":"64","author":"E Vamos","year":"2010","unstructured":"Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington\u2019s disease. Biomed Pharmacother 64:282\u2013286. https:\/\/doi.org\/10.1016\/j.biopha.2009.06.020","journal-title":"Biomed Pharmacother"},{"key":"3069_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10048-003-0169-5","volume":"5","author":"A van Dellen","year":"2004","unstructured":"van Dellen A, Hannan AJ (2004) Genetic and environmental factors in the pathogenesis of Huntington\u2019s disease. Neurogenetics 5:9\u201317. https:\/\/doi.org\/10.1007\/s10048-003-0169-5","journal-title":"Neurogenetics"},{"key":"3069_CR65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pbb.2015.03.002","volume":"132","author":"G Veres","year":"2015","unstructured":"Veres G, Moln\u00e1r M, Z\u00e1dori D, Szentirmai M, Szal\u00e1rdy L, T\u00f6r\u00f6k R et al (2015) Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington\u2019s disease. Pharmacol Biochem Behav 132:115\u2013124. https:\/\/doi.org\/10.1016\/j.pbb.2015.03.002","journal-title":"Pharmacol Biochem Behav"},{"key":"3069_CR66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr et al (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44:559\u2013577. https:\/\/doi.org\/10.1097\/00005072-198511000-00003","journal-title":"J Neuropathol Exp Neurol"},{"key":"3069_CR67","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/jcb.22795","volume":"111","author":"Y Yang","year":"2010","unstructured":"Yang Y, Hubbard BP, Sinclair DA, Tong Q (2010) Characterization of murine SIRT3 transcript variants and corresponding protein products. J Cell Biochem 111:1051\u20131058. https:\/\/doi.org\/10.1002\/jcb.22795","journal-title":"J Cell Biochem"},{"key":"3069_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","volume":"94","author":"D Z\u00e1dori","year":"2009","unstructured":"Z\u00e1dori D, Geisz A, V\u00e1mos E, V\u00e9csei L, Kliv\u00e9nyi P (2009) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington\u2019s disease. Pharmacol Biochem Behav 94:148\u2013153. https:\/\/doi.org\/10.1016\/j.pbb.2009.08.001","journal-title":"Pharmacol Biochem Behav"},{"key":"3069_CR69","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00702-010-0573-6","volume":"118","author":"D Z\u00e1dori","year":"2011","unstructured":"Z\u00e1dori D, Nyiri G, Szonyi A, Szatm\u00e1ri I, F\u00fcl\u00f6p F, Toldi J et al (2011) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington\u2019s disease. J Neural Transm (Vienna) 118:865\u2013875. https:\/\/doi.org\/10.1007\/s00702-010-0573-6","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-020-03069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-020-03069-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-020-03069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:51:04Z","timestamp":1623282664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-020-03069-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s11064-020-03069-0","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}